Suppr超能文献

光学拆分的9-氟丙基-二氢丁苯那嗪作为靶向囊泡单胺转运体的潜在正电子发射断层显像(PET)显像剂的表征

Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.

作者信息

Kung Mei-Ping, Hou Catherine, Goswami Rajesh, Ponde Datta E, Kilbourn Michael R, Kung Hank F

机构信息

Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA.

出版信息

Nucl Med Biol. 2007 Apr;34(3):239-46. doi: 10.1016/j.nucmedbio.2006.12.005.

Abstract

Labeling derivatives of dihydrotetrabenazine (DTBZ) with F-18 (T(1/2)=110 min) instead of C-11 (T(1/2)=20 min) would improve their utility and availability for imaging vesicular monoamine transporters (VMAT2) in clinical settings. The successful synthesis, reported previously, of two novel 9-fluoroalkyl(+/-)-DTBZ ligands prompted us to study the optically resolved active ligand 9-fluoropropyl-(+)-DTBZ (FP-(+)-DTBZ), which may have more promising characteristics. The inhibition constant (K(i)) estimated for FP-(+)-DTBZ (using (3)H-DTBZ as the labeled ligand in rat striatal homogenates) showed a lower value as compared to the racemic FP-(+/-)-DTBZ (0.10+/-0.01 vs 0.19+/-0.04 nM). The inactive isomer, FP-(-)-DTBZ, displayed a much lower binding affinity with a K(i) value >3000 nM. Biodistribution studies in mice after an iv injection of [(18)F]FP-(+)-DTBZ exhibited a ratio of striatum (ST, target) to cerebellum (CB, background) of 4.51 at 30 min postinjection, which is a higher value than previously obtained with the racemic ligand [(18)F]FP-(+/-)-DTBZ (ST/CB=2.95). Brain extraction at 30 min after the tracer injection in mice showed that >95% of the radioactivity corresponded to the parent, nonmetabolized, compound remaining in the ST, suggesting that the tracer has an excellent in vivo stability. Furthermore, localization of the tracer in the brain examined with ex vivo autoradiography displayed a typical distribution pattern consistent with VMAT2 sites. The highest labeling was observed in monoaminergic neuron regions (caudate putamen, olfactory tubercle, nucleus accumbens, substantia nigra, dorsal raphe and locus coerules). We also tested the selective labeling of this tracer at the dopamine neurons in unilateral-lesioned mice (treated with 6-hydroxydopamine). When [(18)F]FP-(+)-DTBZ and [(125)I]IPT ((N-(3'-iodopropen-2'-yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane, a selective marker for dopamine transporters (DATs) in dopaminergic neurons) were simultaneously injected into lesioned mice, we observed an excellent correlation (r=0.95) for these tracers. From these findings, we conclude that [(18)F]FP-(+)-DTBZ is a sensitive and selective tracer for VMAT2 binding sites and it may be useful for in vivo evaluation of diseases relating to changes of monoamine neuronal integrity.

摘要

用氟 - 18(半衰期(T(1/2)=110)分钟)而非碳 - 11(半衰期(T(1/2)=20)分钟)标记二氢丁苯那嗪(DTBZ)的衍生物,将提高其在临床环境中用于成像囊泡单胺转运体(VMAT2)的效用和可及性。先前报道成功合成了两种新型的9 - 氟烷基(±) - DTBZ配体,这促使我们研究光学拆分的活性配体9 - 氟丙基 - (+) - DTBZ(FP - (+) - DTBZ),其可能具有更有前景的特性。用[³H](±) - DTBZ作为标记配体在大鼠纹状体匀浆中估算的FP - (+) - DTBZ的抑制常数((K_i))与外消旋的FP - (±) - DTBZ相比显示出较低的值((0.10 ± 0.01)对(0.19 ± 0.04) nM)。无活性异构体FP - ( - ) - DTBZ表现出低得多的结合亲和力,其(K_i)值(>3000) nM。静脉注射[¹⁸F]FP - (+) - DTBZ后在小鼠中的生物分布研究显示,注射后30分钟时纹状体(ST,靶器官)与小脑(CB,背景)的比值为4.51,这一值高于先前用外消旋配体[¹⁸F]FP - (±) - DTBZ获得的值(ST/CB = 2.95)。在小鼠中注射示踪剂后30分钟时的脑摄取显示,超过95%的放射性对应于留在纹状体中的母体、未代谢的化合物,这表明该示踪剂在体内具有出色的稳定性。此外,用离体放射自显影检查示踪剂在脑中的定位显示出与VMAT2位点一致的典型分布模式。在单胺能神经元区域(尾状壳核、嗅结节、伏隔核、黑质、中缝背核和蓝斑)观察到最高的标记。我们还在单侧损伤小鼠(用6 - 羟基多巴胺处理)中测试了该示踪剂对多巴胺能神经元的选择性标记。当将[¹⁸F]FP - (+) - DTBZ和[¹²⁵I]IPT(N - (3'-碘丙烯 - 2'-基) - 2 - β - 甲氧基羰基 - 3 - β - (4 - 氯苯基)托烷,多巴胺能神经元中多巴胺转运体(DAT)的选择性标记物)同时注射到损伤小鼠中时,我们观察到这些示踪剂之间具有极好的相关性((r = 0.95))。基于这些发现,我们得出结论,[¹⁸F]FP - (+) - DTBZ是VMAT2结合位点的敏感且选择性示踪剂,它可能有助于对与单胺神经元完整性变化相关疾病的体内评估。

相似文献

4
Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain.
Nucl Med Biol. 2007 Apr;34(3):233-7. doi: 10.1016/j.nucmedbio.2007.01.007.
5
In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus.
J Nucl Med. 2008 Jul;49(7):1171-6. doi: 10.2967/jnumed.108.051680. Epub 2008 Jun 13.
6
Effects of anesthetics on vesicular monoamine transporter type 2 binding to ¹⁸F-FP-(+)-DTBZ: a biodistribution study in rat brain.
Nucl Med Biol. 2016 Jan;43(1):124-129. doi: 10.1016/j.nucmedbio.2015.09.009. Epub 2015 Oct 3.
8
An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [F]FP-(+)-DTBZ.
Mol Imaging Biol. 2020 Apr;22(2):265-273. doi: 10.1007/s11307-019-01379-6.
9
Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of F-FP-DTBZ in baboons.
Nucl Med Biol. 2016 Dec;43(12):743-751. doi: 10.1016/j.nucmedbio.2016.08.018. Epub 2016 Sep 2.

引用本文的文献

1
Radiopharmaceuticals and their applications in medicine.
Signal Transduct Target Ther. 2025 Jan 3;10(1):1. doi: 10.1038/s41392-024-02041-6.
2
Diagnostic value of striatal F-FP-DTBZ PET in Parkinson's disease.
Front Aging Neurosci. 2022 Jul 22;14:931015. doi: 10.3389/fnagi.2022.931015. eCollection 2022.
3
A Purification Method of F-FP-(+)-DTBZ Solid-Phase Extraction With Combined Cartridges.
Front Med (Lausanne). 2021 Jul 9;8:693632. doi: 10.3389/fmed.2021.693632. eCollection 2021.
4
An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [F]FP-(+)-DTBZ.
Mol Imaging Biol. 2020 Apr;22(2):265-273. doi: 10.1007/s11307-019-01379-6.
5
Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging.
Diabetologia. 2018 Dec;61(12):2598-2607. doi: 10.1007/s00125-018-4624-0. Epub 2018 May 2.
6
Study of Vesicular Monoamine Transporter 2 in Myopic Retina Using [F]FP-(+)-DTBZ.
Mol Imaging Biol. 2018 Oct;20(5):771-779. doi: 10.1007/s11307-018-1183-1.
9
Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of F-FP-DTBZ in baboons.
Nucl Med Biol. 2016 Dec;43(12):743-751. doi: 10.1016/j.nucmedbio.2016.08.018. Epub 2016 Sep 2.
10
Cross-sectional and Test-Retest Characterization of PET with [(18)F]FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes.
Mol Imaging Biol. 2016 Apr;18(2):292-301. doi: 10.1007/s11307-015-0888-7. Epub 2015 Sep 14.

本文引用的文献

3
Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.
J Cereb Blood Flow Metab. 2006 Sep;26(9):1198-212. doi: 10.1038/sj.jcbfm.9600276. Epub 2006 Jan 18.
4
Rapid loss of striatal VMAT2 binding associated with onset of Lewy body dementia.
Mov Disord. 2006 Feb;21(2):287-8. doi: 10.1002/mds.20733.
6
The role of radiotracer imaging in Parkinson disease.
Neurology. 2005 Jan 25;64(2):208-15. doi: 10.1212/01.WNL.0000149403.14458.7F.
7
Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis.
Arch Neurol. 2004 Dec;61(12):1920-5. doi: 10.1001/archneur.61.12.1920.
8
Increased ventral striatal monoaminergic innervation in Tourette syndrome.
Neurology. 2003 Aug 12;61(3):310-5. doi: 10.1212/01.wnl.0000076181.39162.fc.
10
Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Against.
Eur J Nucl Med Mol Imaging. 2002 May;29(5):715-7. doi: 10.1007/s00259-002-0815-4. Epub 2002 Mar 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验